- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Adjuvanted RSVPreF3 vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Lexington, Kentucky • St Louis, Missouri • Omaha, Nebraska + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine (GSK3844766A)
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Lenexa, Kansas • Elkridge, Maryland • Omaha, Nebraska + 4 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Arexvy (2 doses total), Arexvy (3 doses total), Arexvy (1 dose total), Placebo
- Biological · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland